BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 108,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $2.57, for a total transaction of $277,560.00. Following the completion of the transaction, the director now directly owns 1,759,262 shares in the company, valued at $4,521,303.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded up $0.12 during trading on Friday, reaching $2.70. 532,970 shares of the company’s stock were exchanged, compared to its average volume of 599,860. BioDelivery Sciences International, Inc. has a 1 year low of $1.55 and a 1 year high of $3.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. The firm has a market capitalization of $150.89, a price-to-earnings ratio of 30.00 and a beta of 0.74.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The firm had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. During the same quarter last year, the business posted ($0.30) earnings per share. The company’s quarterly revenue was up 215.1% on a year-over-year basis. research analysts expect that BioDelivery Sciences International, Inc. will post 0.16 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 22nd. HC Wainwright set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average target price of $4.29.

A number of institutional investors have recently modified their holdings of BDSI. Wells Fargo & Company MN boosted its position in BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 20,599 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in BioDelivery Sciences International in the third quarter valued at approximately $116,000. Advisor Group Inc. boosted its position in BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of BioDelivery Sciences International by 0.9% during the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after purchasing an additional 1,203 shares during the period. Finally, Krilogy Financial LLC lifted its holdings in shares of BioDelivery Sciences International by 28.8% during the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 30,000 shares during the period. Hedge funds and other institutional investors own 44.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/19/biodelivery-sciences-international-inc-bdsi-director-mark-a-sirgo-sells-108000-shares.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.